Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$22.90 USD
-0.60 (-2.55%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $22.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
STOK 22.90 -0.60(-2.55%)
Will STOK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STOK
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Other News for STOK
1,2,3 Pullback Bullish appears for STOK after 3.34% move
The technical outlook for STOK is unchanged after it falls 1.81% on September 18
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc
STOK forms Boomer Buy Setup on September 16
STOK forms Upper Bollinger Band Walk on September 15